211 related articles for article (PubMed ID: 25794004)
21. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.
Crona J; Delgado Verdugo A; Maharjan R; Stålberg P; Granberg D; Hellman P; Björklund P
J Clin Endocrinol Metab; 2013 Jul; 98(7):E1266-71. PubMed ID: 23640968
[TBL] [Abstract][Full Text] [Related]
22. Survivin: a novel neuroendocrine marker for pheochromocytoma.
Koch CA; Vortmeyer AO; Diallo R; Poremba C; Giordano TJ; Sanders D; Bornstein SR; Chrousos GP; Pacak K
Eur J Endocrinol; 2002 Mar; 146(3):381-8. PubMed ID: 11888845
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas.
Guo D; Zhao X; Wang A; Xie Q; Xu X; Sun J
Hum Pathol; 2019 Apr; 86():155-162. PubMed ID: 30594747
[TBL] [Abstract][Full Text] [Related]
24. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
[TBL] [Abstract][Full Text] [Related]
25. Paraganglioma: not just an extra-adrenal pheochromocytoma.
Laird AM; Gauger PG; Doherty GM; Miller BS
Langenbecks Arch Surg; 2012 Feb; 397(2):247-53. PubMed ID: 22086065
[TBL] [Abstract][Full Text] [Related]
26. Cancer Stem Cells in Pheochromocytoma and Paraganglioma.
Scriba LD; Bornstein SR; Santambrogio A; Mueller G; Huebner A; Hauer J; Schedl A; Wielockx B; Eisenhofer G; Andoniadou CL; Steenblock C
Front Endocrinol (Lausanne); 2020; 11():79. PubMed ID: 32158431
[TBL] [Abstract][Full Text] [Related]
27. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.
Comino-Méndez I; de Cubas AA; Bernal C; Álvarez-Escolá C; Sánchez-Malo C; Ramírez-Tortosa CL; Pedrinaci S; Rapizzi E; Ercolino T; Bernini G; Bacca A; Letón R; Pita G; Alonso MR; Leandro-García LJ; Gómez-Graña A; Inglada-Pérez L; Mancikova V; Rodríguez-Antona C; Mannelli M; Robledo M; Cascón A
Hum Mol Genet; 2013 Jun; 22(11):2169-76. PubMed ID: 23418310
[TBL] [Abstract][Full Text] [Related]
28. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.
Kumaki N; Kajiwara H; Kameyama K; DeLellis RA; Asa SL; Osamura RY; Takami H
Endocr Pathol; 2002; 13(2):149-56. PubMed ID: 12165664
[TBL] [Abstract][Full Text] [Related]
29. Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options.
Nölting S; Grossman A; Pacak K
Exp Clin Endocrinol Diabetes; 2019 Feb; 127(2-03):117-128. PubMed ID: 30235495
[TBL] [Abstract][Full Text] [Related]
30. New Insights into Pheochromocytoma Biology: the Role of the Insulin - Like Growth Factor 1 (IGF1) System.
Pennisi PA; Fernández MC; Martin A
Pediatr Endocrinol Rev; 2020 Aug; 17(4):331-342. PubMed ID: 32780957
[TBL] [Abstract][Full Text] [Related]
31. DNA flow cytometry in pheochromocytoma and paraganglioma.
Jung WH; Yang WI; Park C; Choi IJ
Yonsei Med J; 1992 Sep; 33(3):249-57. PubMed ID: 1292249
[TBL] [Abstract][Full Text] [Related]
32. Malignancy in pheochromocytomas.
Salmenkivi K; Heikkilä P; Haglund C; Arola J
APMIS; 2004 Sep; 112(9):551-9. PubMed ID: 15601303
[TBL] [Abstract][Full Text] [Related]
33. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors.
Favier J; Plouin PF; Corvol P; Gasc JM
Am J Pathol; 2002 Oct; 161(4):1235-46. PubMed ID: 12368197
[TBL] [Abstract][Full Text] [Related]
34. [Pheochromocytoma and sympathetic paragangliomas].
Zollinger R; Hedinger C
Schweiz Med Wochenschr; 1983 Jul; 113(30):1057-65. PubMed ID: 6623024
[TBL] [Abstract][Full Text] [Related]
35. Histological features, Ki-67 and Bcl-2 immunohistochemical expression and their correlation with the aggressiveness of pheochromocytomas.
Jovanovic R; Kostadinova-Kunovska S; Bogoeva B; Spasevska L; Petrusevska G
Prilozi; 2012; 33(2):23-40. PubMed ID: 23425867
[TBL] [Abstract][Full Text] [Related]
36. Tumor angiogenesis in pheochromocytomas and paragangliomas.
Liu Q; Djuricin G; Staren ED; Gattuso P; Gould VE; Shen J; Saclarides T; Rubin DB; Prinz RA
Surgery; 1996 Dec; 120(6):938-42; discussion 942-3. PubMed ID: 8957477
[TBL] [Abstract][Full Text] [Related]
37. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations.
Oudijk L; Neuhofer CM; Lichtenauer UD; Papathomas TG; Korpershoek E; Stoop H; Oosterhuis JW; Smid M; Restuccia DF; Robledo M; de Cubas AA; Mannelli M; Gimenez-Roqueplo AP; Dinjens WN; Beuschlein F; de Krijger RR
Eur J Endocrinol; 2015 Jul; 173(1):43-52. PubMed ID: 25916394
[TBL] [Abstract][Full Text] [Related]
39. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
40. Malignancy in Pheochromocytoma or Paraganglioma: Integrative Analysis of 176 Cases in TCGA.
Suh YJ; Choe JY; Park HJ
Endocr Pathol; 2017 Jun; 28(2):159-164. PubMed ID: 28386672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
